Trial Profile
Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Capivasertib (Primary) ; Paclitaxel
- Indications Gastric cancer
- Focus Therapeutic Use
- Sponsors Samsung Medical Center
- 26 Dec 2019 Status changed from recruiting to completed.
- 26 May 2015 New trial record